Published in J Virol on February 01, 2004
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J Immunol (2012) 0.83
CD8+ T-cell cross-competition is governed by peptide-MHC class I stability. Eur J Immunol (2011) 0.81
Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunol Immunother (2007) 0.79
Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology (2007) 0.78
Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. J Immunother (2008) 0.78
T cell receptor antagonist peptides induce positive selection. Cell (1994) 18.66
T cell tolerance by clonal elimination in the thymus. Cell (1987) 13.83
Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature (1988) 11.55
Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol (1981) 9.86
Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 8.16
Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol (1999) 7.18
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
Evidence for a differential avidity model of T cell selection in the thymus. Cell (1994) 5.24
T-cell-receptor affinity and thymocyte positive selection. Nature (1996) 4.96
Peripheral selection of the T cell repertoire. Science (1991) 4.56
Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol (1998) 4.54
Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol (1993) 4.23
T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med (2000) 4.16
Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity (1998) 4.15
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol (1999) 3.33
Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity (1995) 3.18
T cell affinity maturation by selective expansion during infection. J Exp Med (1999) 3.08
Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol (2001) 3.08
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science (1994) 2.86
Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell (1991) 2.83
Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity (2000) 2.71
How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity (1994) 2.56
Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol (2001) 2.51
Deletion of autospecific T cells in T cell receptor (TCR) transgenic mice spares cells with normal TCR levels and low levels of CD8 molecules. J Exp Med (1989) 2.35
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med (2000) 2.18
Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10
SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumours in transgenic mice. Nature (1985) 2.10
Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity (1998) 1.97
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90
Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med (1997) 1.73
Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med (1998) 1.70
Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity (1999) 1.61
Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A (1994) 1.56
The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. Eur J Immunol (1991) 1.49
Epitope specificity of H-2Kb-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. Virology (1993) 1.44
Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A (1999) 1.30
Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol (1999) 1.28
Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J Virol (1987) 1.24
Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol (1995) 1.18
Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J Immunol (2002) 1.17
A comparison of several lines of transgenic mice containing the SV40 early genes. Cold Spring Harb Symp Quant Biol (1985) 1.14
Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. Virology (1988) 1.10
Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med (1996) 1.10
An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol (1998) 1.09
Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes. J Exp Med (1992) 1.07
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol (2002) 1.06
Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol (1996) 1.05
Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol (1999) 1.00
Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur J Immunol (2000) 0.97
Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J Virol (1999) 0.96
Comparative analysis of core amino acid residues of H-2D(b)-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. J Virol (1992) 0.96
T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol (2000) 0.96
Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology (1989) 0.95
Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen. Virology (1995) 0.94
Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy. J Immunol (2003) 0.93
Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res (2000) 0.93
Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels. Cell Immunol (1994) 0.92
Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A (2002) 0.92
Dose-dependent T cell tolerance to an immunodominant self peptide. Eur J Immunol (1994) 0.91
Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother (2001) 0.91
Loss of immunorecessive cytotoxic T lymphocyte determinant V on SV40 T antigen following cocultivation with site-specific cytotoxic T lymphocyte clone Y-5. Intervirology (1990) 0.89
Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen. J Immunol (2001) 0.88
Hen egg-white lysozyme-specific T cells elicited in hen egg-white lysozyme-transgenic mice retain an imprint of self-tolerance. J Immunol (1993) 0.86
Influence of antigen density on degree of clonal deletion in T cell receptor transgenic mice. Int Immunol (1992) 0.86
Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J Virol (1995) 0.85
Expression and immune recognition of SV40 Tag in transgenic mice that develop metastatic osteosarcomas. Transgenic Res (2000) 0.83
Frequency analysis of simian virus 40-specific cytotoxic T lymphocyte precursors in the high responder C57BL/6 mouse strain. J Gen Virol (1988) 0.80
Comparison of the T cell receptors on insulin-specific hybridomas from insulin transgenic and nontransgenic mice. Loss of a subpopulation of self-reactive clones. J Immunol (1992) 0.79
Harnessing self-reactivity in cancer immunotherapy. Semin Immunol (1996) 0.77